Literature DB >> 7768649

Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy.

B A Teicher1, S A Holden, G Ara, N P Dupuis, F Liu, J Yuan, M Ikebe, Y Kakeji.   

Abstract

Tissue oxygen tensions were measured in subcutaneously growing rat 9L gliosarcoma under normal air and carbogen breathing conditions prior to and after i.v. administration of a perflubron emulsion. When these animals were treated with the anti-angiogenic agents TNP-470 and minocycline for 5 days prior to oxygen measurement, tumor hypoxia was decreased compared with untreated tumors. Hypoxia, defined as the percent of pO2 readings < or = 5 mm Hg, was decreased from 71% in untreated air-breathing controls to 34% in animals treated with the anti-angiogenic agents, the perflubron emulsion and carbogen breathing. These effects were manifest in the increased response of the tumor to single-dose (10, 20 and 30 Gy) radiation therapy. Twenty-four hours after treatment with BCNU oxygenation of the tumors was not altered; however, 24 hr after administration of adriamycin oxygenation of the tumors was increased such that hypoxia in adriamycin-treated tumors in animals receiving the perflubron emulsion and carbogen was reduced to 21%. Tumor growth delay in the s.c. tumors was increased by the addition of treatment with the anti-angiogenic agents from day 4 through day 18 post-tumor cell implantation along with BCNU or adriamycin on days 7-11. Administration of the perflubron emulsion and carbogen breathing resulted in increased tumor growth delay with the chemotherapeutic agents alone and in combination with the anti-angiogenic agents. Life span in animals bearing intracranially implanted 9L gliosarcoma progressively increased with administration of the anti-angiogenic agents and then the anti-angiogenic agents and perflubron emulsion/carbogen compared to treatment with BCNU or adriamycin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768649     DOI: 10.1002/ijc.2910610523

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

Review 1.  Targeting angiogenesis in bladder cancer.

Authors:  Aymen A Elfiky; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

Review 2.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

3.  Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

Authors:  Limin Hu; Judith Hofmann; Charles Zaloudek; Napoleone Ferrara; Thomas Hamilton; Robert B Jaffe
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 4.  Models for assessment of angiogenesis in gliomas.

Authors:  R H Goldbrunner; S Wagner; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.

Authors:  Y Kakeji; B A Teicher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

6.  Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro.

Authors:  E S Didier
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin.

Authors:  Ai-Li Shiau; Min-Li Teo; Shin-Yao Chen; Chrong-Reen Wang; Jeng-Long Hsieh; Meng-Ya Chang; Chih-Jui Chang; Julie Chao; Lee Chao; Chao-Liang Wu; Che-Hsin Lee
Journal:  BMC Cancer       Date:  2010-05-31       Impact factor: 4.430

Review 8.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

9.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.

Authors:  H Ian Robins; Anne O'Neill; Mark Gilbert; Mark Olsen; Ronald Sapiente; Brian Berkey; Minesh Mehta
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-20       Impact factor: 3.333

10.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

Authors:  H Wildiers; G Guetens; G De Boeck; E Verbeken; B Landuyt; W Landuyt; E A de Bruijn; A T van Oosterom
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.